Update: User programmes underway
Pacific Edge’s bladder cancer diagnostics tests have been available in the US, New Zealand and Australia for over a year and initial sales indicate a steady ramping-up of adoption in both new customers embarking on User Programmes, as well as initial evaluations and commercial sales from existing customers. We expect news related to the conversion of these programmes into full commercial contracts in the next year. Negotiations are also well underway with key public health organisations in the US – CMS (Centers for Medicare & Medicaid Services) and the VA (Veteran’s Administration). Meanwhile, the company continues to build a world-wide patent estate around its additional genetic-based cancer diagnostic tests.Pacific Edge is engaged in the biotechnology research, development and the commercialization of methods of early detection and treatment of cancers and other genetics diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.